Prevail Innovative Wealth Advisors LLC Buys New Stake in Regeneron Pharmaceuticals, Inc. $REGN

Prevail Innovative Wealth Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, HoldingsChannel reports. The firm acquired 7,628 shares of the biopharmaceutical company’s stock, valued at approximately $4,289,000.

Several other institutional investors have also bought and sold shares of the stock. Salomon & Ludwin LLC acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $31,000. Caitlin John LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $34,000. Traub Capital Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $38,000. Finally, Berbice Capital Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 300.0% in the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 60 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the sale, the director owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. This trade represents a 0.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the transaction, the senior vice president directly owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 5,274 shares of company stock worth $4,142,738. Insiders own 7.02% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on REGN shares. Guggenheim increased their price objective on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Canaccord Genuity Group lifted their target price on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Evercore boosted their target price on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research report on Thursday, January 22nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, December 29th. Finally, Scotiabank increased their price target on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a research report on Monday, November 24th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $802.27.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $759.82 on Friday. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $80.33 billion, a price-to-earnings ratio of 18.28, a P/E/G ratio of 2.04 and a beta of 0.41. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The firm has a 50 day moving average of $770.81 and a two-hundred day moving average of $688.75.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $12.07 earnings per share. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were given a $0.94 dividend. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend was Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.05%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.